Should you invest £1,000 in these two growth monsters today?

Harvey Jones analyses just how far your money will travel if you invest it in these two monster growth stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Engineering data and design IT systems provider Aveva Group (LSE: AVV) has been setting the pace in the last six months, its share price jumping an incredible 48% in that time.

Viva Aveva

It is relatively becalmed today, rising only slightly on publication of the briefest of trading updates to mark today’s announcement of the 2017 financial results at French-owned Schneider Electric. It bought a majority stake in Aveva last year and its industrial software portfolio shares corresponding assets. This reported continued growth in its licensing and maintenance revenue streams, partly offset by a slight decline in services revenue.

Expensive

Do check out this article by my Foolish colleague Peter Stephens, who warned that this stock could lose you a fortune because it risks being overvalued, which is always a danger with growth monsters like this one. However, Aveva at the moment looks to have earned its success after posting strong performance in the first nine months of its financial year, across all reporting regions with a particularly good performance in Asia Pacific.

The share price surge has pumped up its valuation to a hefty forecast 36.8 times earnings, while its PEG ratio stands at an equally stretched 3.3. Those two numbers will be enough to put many potential investors off but there is growth in the pipeline, according to City analysts, who forecast an increase in earnings per share (EPS) of a healthy 11% in the year to 31 March 2018, followed by 5% and then 9%. So the share price could keep rising, but it shouldn’t be too hard to find a better home for your £1,000 today.

Nice IDEA

Could that home be high-growth technology play Ideagen (LSE: IDEA)? The company supplies information management software to highly regulated industries and its stock spiked 20% at the end of January following publication of its unaudited interim results for the six months to 31 October.

This buoyant set of figures showed revenue increasing 43% to £17.2m, with underlying organic revenue growth of 13%. New bookings increased 78% to £10.8m while recurring revenues increased 60% to £10.8m. My colleague Alan Oscroft flagged up its success at the time, and said he admired a business that benefits from a captive clientele and high barriers to entry.

The gen on Ideagen

Ideagen has now posted five consecutive years of double-digit EPS growth with another 27% forecast in the year to 30 April 2018, followed by 10% after that. Once again, its pricey valuation reflects the recent share price surge, with the stock trading at 34.2 times earnings, although this is expected to calm down by 2019, to 24.6 times.

Before you part with your £1,000, make sure you understand the risks as well as the potential rewards. This AIM-listed software developer has a market cap of just £227m and needs to constantly build revenue sources to justify high investor expectations, so any slippage could prove costly. In January it won a new audit software contract with Commerzbank and will need more of that to keep rattling along. This probably should not be the first stock to pop in a newbie portfolio, but it could add some zip to an existing one.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »